Everest gets rights to Tetraphase antibiotic

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) granted C-Bridge-backed Everest Medicines Ltd. (Boston, Mass.) exclusive rights to develop and commercialize eravacycline (TP-434) in China, Taiwan, Hong Kong, Macau, South Korea and Singapore.

Tetraphase

Read the full 291 word article

User Sign In